Visiongain launches new report on Gene Therapy R&D and Revenue Forecasts 2018-2028

Prospects for Drugs Treating Cancer, Cardiovascular Disorders, Rare Diseases, Ophthalmologic Conditions, Other Diseases, Approved Gene therapies, R&D Pipeline Analysis, Gene Therapy Regulations by Region and Leading Players


LONDON, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Gene Therapy Market set to Grow at a CAGR of 41.1% in the first half of the forecast period.

Visiongain has launched a new pharma report: Gene Therapy R&D and Revenue Forecasts 2018-2028: Prospects for Drugs Treating Cancer, Cardiovascular Disorders, Rare Diseases, Ophthalmologic Conditions, Other Diseases, Approved Gene therapies, R&D Pipeline Analysis, Gene Therapy Regulations by Region and Leading Players.

The gene therapy market is still establishing itself and many opportunities are available to explore at the moment. One opportunity in this market is for smaller biotechnology companies, which because of their size and infrastructure may be able to develop an orphan drug quicker than a Big Pharma company can. Another opportunity in the gene therapy market is the development of novel technologies such as CRISPR (clustered regularly interspaced short palindromic repeats). Gene therapy has seen many advances in recent years, such as improvement in viral vector delivery for safe and efficacious gene delivery and expression.

The lead analyst of the report commented, The growth of the overall gene therapy market will be driven by the immense pipeline of gene therapies in development. Many gene therapies in development target orphan diseases with high unmet need, this pipeline includes therapies that cover a wide range of indications for the cancer, cardiovascular, ophthalmologic, rare diseases, musculoskeletal, neurodegenerative and metabolic disease submarkets among others.

“Clinical trials so far have demonstrated favourable results in a broad range of indications with treatments predicted to launch in the next few years for the cardiovascular disease, rare disease, and cancer submarkets.”

To read a free report overview please email sara.peerun@visiongain.com or click on https://www.visiongain.com/report/gene-therapy-rd-and-revenue-forecasts-2018-2028/

Leading companies featured in the report include UniQure, Biogen, Bluebird Bio, Spark Therapeutics, Applied Genetics Technologies Corporation, Oxford Biomedica, GenSight Biologics and other leading companies currently developing gene therapies. Leading Big Pharma Companies mentioned in this report include Bristol-Myers Squibb, Pfizer, Bayer, Novartis, Roche, Sanofi & GSK.

Full list of companies mentioned in the report include:

4DMT (4D Molecular Therapeutics)

Abeona

AGTC (Applied Genetics Technologies Corporation)

AMT (Amsterdam Molecular Therapeutics)

AnGes MG

Asklepios BioPharma

AstraZeneca

Audentes Therapeutics

Avalanche Biotech

Bayer Healthcare

Beijing Northland Biotech Co

Benda Pharmaceutical

Benitec Biopharma

BioCancell

Biogen

Biogen Idec

Bluebird Bio

BMS (Bristol-Myers Squibb)

Broad Institute/Whitehead Institute

Celgene

Cell Therapy Catapult

Cellectis

Chiesi Farmaceutici

Clearside Biomedical

Convergence Pharmaceuticals

Daiichi Sankyo

Dimension Therapeutics

Editas Medicine

Fondazione Telethon

Francis Crick Institute

Genable Technologies Ltd

Genethon

GenSight Biologics

GenVec

Google

GSK (GlaxoSmithKline)

Henry Ford Health System

HSCI (Human Stem Cells Institute)

HSR-TIGET (San Raffaele Telethon Institute for Gene Therapy),

ImaginAb

Immune Design Corp

InoCard

Inovio

Intellia Therapeutics

Invetech

Kite Pharma

Kolon Group

Kolon Life Science

Lysogene

Mitsubishi Tanabe Pharma Corporation

Neuralgene

NightstaRx

Northwestern Memorial Hospital

Novartis

OXB (Oxford Biomedica)

Pfizer

PNP Therapeutics

Precision Genome Engineering Inc aka Pregenen

ProNai

Protek Group

Raffaele Hospital

REGENX Biosciences

Renova Therapeutics

Roche

Roszdravnadzor

Sangamo Biosciences

Sanofi

Sarepta Therapeutics

Shanghai Sunway Biotech

Shenzhen SiBiono GeneTech

Sotex Pharm Firm

Spark Therapeutics

SynerGene Therapeutics

Takara Bio

TAP Biosystems

Thermo Fisher Scientific

TissueGene

ToolGen

UC Berkeley

UC San Francisco

UniQure

US Business Innovation Network

Vertex Pharmaceuticals

Vical Incorporated

ViroMed

VM Biopharma

Voyage Therapeutics

To read a free report overview please email sara.peerun@visiongain.com or click on https://www.visiongain.com/report/gene-therapy-rd-and-revenue-forecasts-2018-2028/

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field led by a team of Russel Group university educated editors and researchers. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.